Responses
Poster Presentations
Rheumatoid arthritis - non biologic treatment and small molecules
SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
Compose a Response to This Article
Other responses
No responses have been published for this article.